Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • 2024-05
  • 2024-06
  • 2024-07
  • 2024-08
  • 2024-09
  • 2024-10
  • 2024-11
  • 2024-12
  • AR-C155858 mg br Experimental section br Acknowledgements

    2024-11-11


    Experimental section
    Acknowledgements This work was funded by the Italian Association for Cancer Research (AIRC IG18590 to A.A.), by “Fondi di Ateneo-University of Pisa” years 2009 and 2010 (E. N., S. N., E. O., and A. R.) and partially by the Unipi project P.R.A.2016_27 (E. N., E.O. and A. R.). A.B. is the recipient of a Post-Doctoral Fellowship from Fondazione Umberto Veronesi. B.B. was a participant to the Ph.D. program in Biotechnology, Biosciences and Surgical Technologies, School of Biological and Medical Sciences, University of Insubria. C.C. is the recipient of a Post-Doctoral Fellowship funded by MIUR (PRIN2010, 20109MXHMR_007 to S·N.). C.G. is a student of the PhD program in Biotechnologies and Biosciences, University of Parma. L.R. was a participant to the Ph.D. program in Science of Drug and Bioactive Substances, University of Pisa. A.A. is supported by Fondazione MultiMedica Onlus. Initial studies were sustained by MIUR Grande Progetto Strategico.
    Introduction Skin cancer, including melanoma and non-melanoma types, shows the highest incidence among all types of cancer and the number of new cases in the next decades tends to increase [1]. According to the World Health Organization, around 2.5 million new cases of non-melanoma skin cancer occurs every year [2] and the incidence of melanoma skin type has increased annually by 0.6% in adults over 50 years [3]. This is mainly due to environmental changes and population's lifestyle that makes the epithelium constantly exposed to carcinogens such as tobacco smoke, chemical substances and solar AR-C155858 mg [1,4]. A great number of therapeutic options is available to treat cutaneous neoplasms [5], including simple excision, Mohs micrographic surgery, cryotherapy, curettage, laser, radiotherapy, photodynamic therapy, immunotherapy and chemotherapy [6,7]. Despite so many alternatives and advances in skin cancers therapies [1] failures in clinical outcomes are common in addition to the high cost of these treatments [8]. Under these conditions, chemoprevention, which is the use of products that may prevent or inhibit the development of tumor lesions, is a promising strategy [4]. A large number of compounds have been evaluated for their chemopreventive activity and it is desirable that such components have low toxicity, reduced or absent adverse effects, effectiveness at low dosages and ease administration [9]. Imiquimod (Imq) is a compound approved by the FDA in 2004 for topical treatment of superficial basal cell carcinoma [10]. However, ongoing clinical trials have also demonstrated Imq potential to treat other types of precancerous skin lesions, such as lentigo maligno [11] hemangiomas [12] and cutaneous metastases of breast cancer [13], among others. Imq antitumor activity is recognized mainly through its immunomodulatory action. It binds to TLR 7 endosomal receptors of antigen presenting cells, such as dendritic cells present in the skin, promoting its activation. Once activated, these cells release chemokines and cytokines that stimulate both innate and acquired immune response targeted to the tumor tissue [14]. In addition, Imq also presents antiangiogenic and pro-apoptotic activities already described in vitro and in vivo [15,16] Despite the advantages of the topical use of Imq, that includes the easy application by the patient, less pain, reduced cost when compared to surgical procedures and its therapeutic efficacy [17], there are some limitations associated with the topical therapy with market Imq. Adverse effects and Imq low skin permeation are among these limitations and may impair patient compliance to the treatment and difficult the drug to reach epidermal cells and achieve its antitumor activity, respectively [18,19,20]. During treatment with Imq, skin reactions such as erythema, hypopigmentation and burning are commonly reported [21,22,23,24] which may lead to discontinuation of the treatment. In a study done by Karve and colleagues [18]. more than 50% of the patients reported at least one adverse effect and other effects were also observed as erosions, pustules, edema, hardening and peeling of the skin.